- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/00 - Antineoplastic agents
Patent holdings for IPC class A61P 35/00
Total number of patents in this class: 108698
10-year publication summary
|
2456
|
4431
|
6314
|
6707
|
7829
|
9087
|
9809
|
9903
|
9056
|
1174
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10463 |
986 |
| The Regents of the University of California | 20378 |
921 |
| Genentech, Inc. | 4038 |
766 |
| F. Hoffmann-La Roche AG | 7875 |
745 |
| Bristol-myers Squibb Company | 4810 |
714 |
| Dana-Farber Cancer Institute, Inc. | 2635 |
688 |
| Board of Regents, The University of Texas System | 6010 |
614 |
| Memorial Sloan-Kettering Cancer Center | 1991 |
518 |
| AstraZeneca AB | 2826 |
501 |
| The Johns Hopkins University | 5774 |
489 |
| Hoffmann-La Roche Inc. | 3612 |
475 |
| Merck Patent GmbH | 5724 |
474 |
| Centre National de La Recherche Scientifique | 10805 |
464 |
| Amgen Inc. | 4301 |
452 |
| Incyte Corporation | 1039 |
450 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2945 |
434 |
| Janssen Pharmaceutica N.V. | 3307 |
402 |
| Pfizer Inc. | 3374 |
401 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3354 |
398 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3085 |
398 |
| Other owners | 97408 |